Christoph Oing1,2, Mia-Carlotta Peters3, Felix Bremmer4. 1. Klinik für Onkologie, Hämatologie und Stammzelltransplantation mit Abteilung für Pneumologie, Universitätsklinikum Eppendorf, Martinistr. 52, 20246, Hamburg, Deutschland. c.oing@uke.de. 2. Mildred Scheel Nachwuchszentrum, HaTriCS4, Universitäres Cancer Center Hamburg, Universitätsklinikum Eppendorf, Martinistr. 52, 20246, Hamburg, Deutschland. c.oing@uke.de. 3. Klinik für Onkologie, Hämatologie und Stammzelltransplantation mit Abteilung für Pneumologie, Universitätsklinikum Eppendorf, Martinistr. 52, 20246, Hamburg, Deutschland. 4. Institut für Pathologie, Universitätsmedizin Göttingen, Robert-Koch-Str. 40, 37075, Göttingen, Deutschland.
Abstract
BACKGROUND: Testicular type II germ cell tumours (GCTs) are an exemplar of a curable cancer and the most common malignancy in males aged ≤35 years. Even in metastatic stages, about 70% of patients can be cured by cisplatin-based chemotherapy and multimodal treatments. For patients failing platinum-based standard therapy, prognosis is poor and novel biomarkers and therapeutic options are urgently needed. OBJECTIVES: Discussion of desired histopathological information to guide urologists' and oncologists' decision making in the treatment of male GCTs. MATERIAL AND METHODS: A narrative review of histopathological key features of male GCT tissue samples for clinical decision making. RESULTS: Histopathological workup is crucial to identify (i) a GCT origin in cancers of unknown primary based on isochromosome 12p (i(12p)) detection, (ii) the different type II GCT subtypes, and (iii) risk factors, i.e. lymphovascular or rete testis invasion, among others. Proper histopathological diagnosis is indispensable for guideline-endorsed, histology-driven, and risk-adapted treatment decisions, hereby helping to maintain treatment success while reducing the therapeutic burden and potential long-term sequelae of multimodal treatments. For refractory patients failing standard treatment options, prognosis remains poor and, so far, neither predictive or prognostic biomarkers nor novel therapeutic targets have been established. CONCLUSIONS: Close interaction and interdisciplinary discussion of histopathologic and radiologic findings and established risk factors including serum tumour markers is crucial for successful treatment including intensified strategies, where necessary, or prevention of overtreatment, where possible.
BACKGROUND: Testicular type II germ cell tumours (GCTs) are an exemplar of a curable cancer and the most common malignancy in males aged ≤35 years. Even in metastatic stages, about 70% of patients can be cured by cisplatin-based chemotherapy and multimodal treatments. For patients failing platinum-based standard therapy, prognosis is poor and novel biomarkers and therapeutic options are urgently needed. OBJECTIVES: Discussion of desired histopathological information to guide urologists' and oncologists' decision making in the treatment of male GCTs. MATERIAL AND METHODS: A narrative review of histopathological key features of male GCT tissue samples for clinical decision making. RESULTS: Histopathological workup is crucial to identify (i) a GCT origin in cancers of unknown primary based on isochromosome 12p (i(12p)) detection, (ii) the different type II GCT subtypes, and (iii) risk factors, i.e. lymphovascular or rete testis invasion, among others. Proper histopathological diagnosis is indispensable for guideline-endorsed, histology-driven, and risk-adapted treatment decisions, hereby helping to maintain treatment success while reducing the therapeutic burden and potential long-term sequelae of multimodal treatments. For refractory patients failing standard treatment options, prognosis remains poor and, so far, neither predictive or prognostic biomarkers nor novel therapeutic targets have been established. CONCLUSIONS: Close interaction and interdisciplinary discussion of histopathologic and radiologic findings and established risk factors including serum tumour markers is crucial for successful treatment including intensified strategies, where necessary, or prevention of overtreatment, where possible.
Authors: K A Kesler; K M Rieger; K N Ganjoo; M Sharma; N S Fineberg; L H Einhorn; J W Brown Journal: J Thorac Cardiovasc Surg Date: 1999-10 Impact factor: 5.209
Authors: M P Brandt; K M Gust; D Bon; I Tsaur; C Thomas; A Neisius; A Haferkamp; E Herrmann; G Bartsch Journal: Andrology Date: 2019-07 Impact factor: 3.842
Authors: Patrizia Giannatempo; Gregory R Pond; Guru Sonpavde; Costantine Albany; Yohann Loriot; Christopher J Sweeney; Roberto Salvioni; Maurizio Colecchia; Nicola Nicolai; Daniele Raggi; Kevin R Rice; Chandra K Flack; Nemer R El Mouallem; Hope Feldman; Karim Fizazi; Lawrence H Einhorn; Richard S Foster; Andrea Necchi; Clint Cary Journal: J Urol Date: 2015-12-31 Impact factor: 7.450
Authors: Alexander Fichtner; Annika Richter; Simon Filmar; Nadine T Gaisa; Stefan Schweyer; Henning Reis; Daniel Nettersheim; Christoph Oing; Fabian A Gayer; Andreas Leha; Stefan Küffer; Philipp Ströbel; Silke Kaulfuß; Felix Bremmer Journal: Histopathology Date: 2020-11-21 Impact factor: 5.087
Authors: Kevin M Kernek; Matteo Brunelli; Thomas M Ulbright; John N Eble; Guido Martignoni; Shaobo Zhang; Helen Michael; Oscar W Cummings; Liang Cheng Journal: Mod Pathol Date: 2004-11 Impact factor: 7.842
Authors: C Bokemeyer; N Schleucher; B Metzner; M Thomas; O Rick; H-J Schmoll; C Kollmannsberger; I Boehlke; L Kanz; J T Hartmann Journal: Br J Cancer Date: 2003-07-07 Impact factor: 7.640